Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...

Merck issued guidance for 2025 that lags consensus ... Those were partially offset by lower sales of diabetic medicines Januvia and Janumet, and lower combined sales of the human papillomavirus ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Merck's Type 2 diabetes treatment, Januvia, also saw sales fall to $487 million during the quarter, down 38% from the same period a year ago. The company said the decline was primarily due to ...